S.I. No. 531/2018 - Health Products Regulatory Authority (Fees) (No. 2) Regulations 2018

(1)(inserted by Regulation 3(a) of the Medicinal Products (Control of Manufacture) (Amendment) Regulations 2013 ( S.I. No. 163 of 2013 )) of the Medicinal Products (Control of Manufacture) Regulations 2007 ( S.I. No. 539 of 2007 ); “authorised representative” means a person established within the European Economic Area who, explicitly designated by the manufacturer, acts for the manufacturer and may be addressed by authorities and bodies in the European Economic Area instead of the manufacturer with respect to the European Communities (Medical Devices) Regulations 1994 ( S.I. No. 252 of 1994 ), the European Communities (Active Implantable Medical Devices) Regulations 1994 ( S.I. No. 253 of 2004 ), or the European Communities (In Vitro Diagnostic Medical Devices) Regulations 2001 ( S.I. No. 304 of 2001 ); “Authority” means the Health Products Regulatory Authority; “breeder authorisation” has the meaning assigned to it by Regulation 3

(1)of the Protection of Animals Regulations; “broker” means a person carrying out the brokering of medicinal products, as defined in Regulation 4

(1)(as amended by Regulation 3 of the Medicinal Products (Control of Wholesale Distribution) (Amendment) Regulations 2013 ( S.I. No. 164 of 2013 )) of the Control of Wholesale Distribution Regulations; “brokers register” has the meaning assigned to it by Regulation 4

(1)(as amended by Regulation 3(a) of the Medicinal Products (Control of Wholesale Distribution) (Amendment) Regulations 2013) of the Control of Wholesale Distribution Regulations; “certificate of free sale” means a certificate of free sale issued under section 4

(1)(k)(ii) (as amended by section 11(a)(iii) of the Act of 2006) of the Act of 1995; “certificate of registration” has the meaning assigned to it by Regulation 3

(1)of the Control of Placing on the Market Regulations; “certificate of traditional-use registration” has the meaning assigned to it by Regulation 3

(1)of the Control of Placing on the Market Regulations; “certification of documents” means the certification, under section 4

(1)(k)(ii) (as amended by section 11(a)(iii) of the Act of 2006) of the Act of 1995, of documents not being certificates of free sale or export certificates; “complex dossier” refers to an application accompanied by a full dossier in accordance with Directive 2001/83/EC; “Control of Placing on the Market Regulations” means the Medicinal Products (Control of Placing on the Market) Regulations 2007 ( S.I. No. 540 of 2007 ); “Control of Wholesale Distribution Regulations” means the Medicinal Products (Control of Wholesale Distribution) Regulations 2007 ( S.I. No. 538 of 2007 ); “decentralised procedure” means the decentralised procedure for human medicinal products provided for in Directive 2001/83/EC; “Directive 2001/83/EC” means Directive 2001/83/EC of the European Parliament and of the Council of 6 November 20011 ; “distributor”, in the context of medical devices, means any natural or legal person in the supply chain, other than the manufacturer or the importer, who makes a medical device available on the market; “listed organisation” has the meaning assigned to it by Regulation 4

(1)(as amended by Regulation 3 of the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 2) Regulations 2015 ( S.I. No. 449 of 2015 )) of the Medicinal Products (Prescription and Control of Supply) Regulations 2003 ( S.I. No. 540 of 2003 ); “export certificate” means an export certificate issued under section 4

(1)(k)(ii) (as amended by section 11(a)(iii) of the Act of 2006) of the Act of 1995; “follow-up inspections” means inspections other than routine inspections; “homeopathic medicinal product” has the meaning assigned to it by Regulation 3

(1)of the Control of Placing on the Market Regulations; “individual authorisation” means an authorisation granted to an individual under Part 8 of the Protection of Animals Regulations; “investigational medicinal product” has the meaning assigned to it by Regulation 3

(1)of the Medicinal Products (Control of Manufacture) Regulations 2007; “manufacturer”, in the context of medical devices, means— (

1. a)a person who is responsible for the design, manufacture, packaging and labelling of a medical device before it is placed on the market under his or her own name, regardless of whether these operations are carried out by that person himself or herself or on his or her behalf by a third party, or (
2. b)a person who assembles, packages, processes, fully refurbishes or labels one or more ready-made products or assigns to them their intended purpose as a medical device with a view to their being placed on the market under his or her own name, but not including a person who assembles or adapts medical devices already on the market to their intended purpose for an individual patient; “manufacturer’s authorisation” has the meaning assigned to it by Regulation 3

(1)of the Medicinal Products (Control of Manufacture) Regulations 2007; “manufacturing site”, in the context of medical devices, means a site where an entity— (

1. a)manufactures a medical device, (
2. b)manufactures critical components of a medical device to a set of specifications, (
3. c)carries out packaging activities in relation to a medical device, or (
4. d)carries out labelling activities in relation to a medical device; “marketing authorisation” means a marketing authorisation granted pursuant to the Control of Placing on the Market Regulations; “medical device” means any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, including the software intended by its manufacturer to be used specifically for diagnostic or therapeutic purposes and necessary for its proper application, intended by the manufacturer to be used for human beings for the purpose of— (
5. a)diagnosis, prevention, monitoring, treatment or alleviation of disease, (
6. b)diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap, (
7. c)investigation, replacement or modification of the anatomy or of a physiological process, or (
8. d)control of conception, and which does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, even if it is assisted in its function by such means, and includes— (
9. i)an in vitro diagnostic medical device in accordance with the European Communities (In Vitro Diagnostic Medical Devices) Regulations 2001, and (
10. ii)an active implantable medical device in accordance with the European Communities (Active Implantable Medical Devices) Regulations 1994; “mutual recognition procedure” means the mutual recognition procedure for human medicinal products provided for in Directive 2001/83/EC; “national rules scheme” means the national rules governing the granting of marketing authorisation in respect of homeopathic medicinal products, as provided in Regulation 11 of the Control of Placing on the Market Regulations; “notified body” means, in relation to any task, a body designated and notified in respect of that task in accordance with the European Communities (Medical Devices) Regulations 1994, the European Communities (Active Implantable Medical Devices) Regulations 1994, or the European Communities (In Vitro Diagnostic Medical Devices) Regulations 2001; “organ establishment authorisation” means an authorisation granted pursuant to Regulation 6 of the European Union (Quality and Safety of Human Organs Intended for Transplantation) Regulations 2012 ( S.I. No. 325 of 2012 ); “parallel import licence” has the meaning assigned to it by Regulation 3

(1)of the Control of Placing on the Market Regulations; “project” and “project authorisation” have the meanings assigned to them by Regulation 3

(1)of the Protection of Animals Regulations; “Protection of Animals Regulations” means the European Union (Protection of Animals used for Scientific Purposes) Regulations 2012 (No. 543 of 2012); “reduced dossier — complex” refers to an application for a generic medicinal product accompanied by a reduced dossier but containing additional data in circumstances required by Directive 2001/83/EC; “reduced dossier — standard” refers to an application for a generic medicinal product accompanied by a reduced dossier in accordance with Directive 2001/83/EC; “service item” means an application for a medicinal product designated by the Authority as qualifying for a reduced application fee on the basis that the product has limited but important uses for which no alternative authorised product exists; “subsequent extension applications” means applications in relation to additional pharmaceutical forms and strengths of a medicinal product, made subsequent to the first application in relation to that product; “supplier authorisation” has the meaning assigned to it by Regulation 3

(1)of the Protection of Animals Regulations; “switching applications” means applications for a change in the classification of medicinal products under Title VI of Directive 2001/83/EC; “traditional herbal medicinal product” has the meaning assigned to it by Regulation 3

(1)of the Control of Placing on the Market Regulations; “type IB variation” and “type II standard variation” refer to classifications by the Authority in accordance with Commission Regulation (EC) No. 1234/2008 of 24 November 20082 ; “user authorisation” has the meaning assigned to it by Regulation 3

(1)of the Protection of Animals Regulations; “wholesaler’s authorisation” has the meaning assigned to it by Regulation 4

(1)of the Medicinal Products (Control of Wholesale Distribution) Regulations

2. Subject to Regulation 4, there shall be paid to the Authority in respect of each and every matter set out in column 1 of the Schedule the corresponding fee set out in column 2 of the Schedule.
3. The Authority may, in circumstances where it considers it appropriate to do so, waive, remit or refund, either in whole or in part, any fee that would otherwise be payable to it under Regulation
5. The Health Products Regulatory Authority (Fees) Regulations 2018 ( S.I. No. 208 of 2018 ) are revoked. SCHEDULE COLUMN 1 COLUMN 2 Fees for national applications for marketing authorisations € Complex dossier National application 20,000 Each additional form (same time) 7,000 Each additional strength (same time) 1,000 Additional drug master file submitted 4,000 Reduced dossier — complex National application 15,000 Each additional form (same time) 7,000 Each additional strength (same time) 1,000 Additional drug master file submitted 4,000 Reduced dossier — standard National application 10,000 Each additional form (same time) 7,000 Each additional strength (same time) 1,000 Additional drug master file submitted 4,000 Subsequent extension applications First additional form 10,000 Each additional form (same time) 7,000 First additional strength (existing form) 3,000 Each additional strength (same time) 1,000 Additional drug master file submitted 4,000 Fees for applications for marketing authorisations using mutual recognition procedure and decentralised procedure Complex dossier Mutual recognition incoming 14,000 Each additional form (same time) 5,000 Each additional strength (same time) 1,000 Outgoing mutual recognition supplement 15,000 Decentralised incoming 20,000 Decentralised outgoing 50,000 Each additional form (same time) 7,000 Each additional strength (same time) 1,000 Additional supplement where there are 15 or more concerned Member States 1,500 Reduced dossier — complex Mutual recognition incoming 10,000 Each additional form (same time) 5,000 Each additional strength (same time) 1,000 Outgoing mutual recognition supplement 15,000 Decentralised incoming 15,000 Decentralised outgoing 40,000 Each additional form (same time) 7,000 Each additional strength (same time) 1,000 Additional supplement where there are 15 or more concerned Member States 1,500 Reduced dossier — standard Mutual recognition incoming 7,000 Each additional form (same time) 4,000 Each additional strength (same time) 1,000 Outgoing mutual recognition supplement 10,000 Decentralised incoming 10,000 Decentralised outgoing 26,000 Each additional form (same time) 7,000 Each additional strength (same time) 1,000 Additional supplement where there are 15 or more concerned Member States 1,500 Subsequent extension applications Mutual recognition incoming (first additional form) 7,000 Mutual recognition incoming (first additional strength) 2,000 Mutual recognition incoming (subsequent additional strength) 1,000 Outgoing mutual recognition/decentralised supplement (additional form) 3,000 Outgoing mutual recognition/decentralised supplement (additional strength) 1,000 Decentralised incoming (first additional form) 10,000 Decentralised outgoing (first additional form) 26,000 Each additional form (same time) 7,000 First additional strength (existing form) 3,000 Each additional strength (same time) 1,000 Additional supplement where there are 15 or more concerned Member States 1,500 Switching applications Switching applications 5,100 Fees for parallel import licences Application fee — per country at the same time or by variation 1,831 Each additional strength per country 545 Each additional form per country 545 Parallel imports — dual pack registration 915 Dual pack registration of parallel imports — each additional strength or form 545 Parallel imports where the originator is not on the Irish market 5,508 Change of ownership per product range 578 Fees for variations to national marketing authorisations Type IB variation 516 Type IB variation — reduced rate 258 Type II complex variation 2,865 Type II complex variation — reduced rate 558 Type II standard variation 558 Type II standard variation — reduced rate 278 Notifications under Article 61

(3)of Directive 2001/83/ EC 275 Notifications under Article 61

(3)of Directive 2001/83/EC — reduced rate 138 Multiple variations capped fee (per product range) 5,288 Multiple variations capped fee (per product) 3,415 Worksharing capped fee 5,728 Fees for variations to marketing authorisations under mutual recognition procedure and decentralised procedure Type IB variation outgoing mutual recognition / decentralised supplement 380 Type IB variation — mutual recognition incoming 372 Type IB variation — mutual recognition incoming — reduced rate 192 Type II complex variation — outgoing mutual recognition / decentralised Supplement 578 Type II complex variation — mutual recognition incoming 1,980 Type II complex variation — mutual recognition incoming — reduced rate 372 Type II standard variation — mutual recognition incoming 372 Type II standard variation — mutual recognition incoming — reduced rate 192 Type II standard variation — outgoing mutual recognition / decentralised Supplement 372 Notifications made under Article 61

(3)of Directive 2001/83/EC 275 Notifications made under Article 61

(3)of Directive 2001/83/EC — reduced rate 138 Fees for the granting of a marketing authorisation on transfer to another company Change of ownership — related company — 1st marketing authorisation within a range 991 Change of ownership — related company — each additional marketing authorisation within a range 354 Change of ownership — non-related company — 1st marketing authorisation within a range 1,450 Change of ownership — non-related company — each additional marketing authorisation within a range 354 Other fees relating to the granting of marketing authorisations Service item 674 Notification to become a listed organisation Notification Fee 10 Fees for applications for wholesaler’s authorisations Application fee 611 Variation to authorisation — minor site technical 441 Variation to authorisation — administrative 241 Variation to authorisation — technical 664 Fees for applications for manufacturer’s authorisations Application fee 2,041 Variation to authorisation — administrative 302 Variation to authorisation — technical 846 Variation to authorisation — investigational medicinal product — fast track 1,200 Fees for applications in relation to brokers register and active substances register Registration fee — importers and distributors of active substances and Brokers 275 Registration fee — manufacturers of active substances 486 Immediate notification of a change which may impact on the quality or safety of the active substances 846 Notification of an administrative change to the active substances register 150 Notification of any change to the brokers register 150 Fees for applications for organ establishment authorisations Application charge 2,041 Variation to authorisation — administrative 302 Variation to authorisation — technical 846 Appeal to amend/revoke an authorisation 551 Fees for transferring of authorisation/registration to another company Manufacturer's authorisation and organ establishment authorisation Related companies 1,219 Unrelated companies 2,041 Wholesaler’s authorisation, registration on brokers register and registration on active substances register Related companies 402 Unrelated companies 611 Fees for applications in relation to cosmetic products Certificates of free sale — standard (4 certs per request) 162 Certificates of free sale — fast track (4 certs per request) 305 Duplicate certificates of free sale — each (available at time of initial request) 25 Fees for applications in relation to homeopathic medicinal products New national / decentralised registration standard charge — single stock 747 New national / decentralised registration standard charge — 2 or more stocks 1,119 New application — national rules scheme standard fee — single stock 1,119 New application — national rules scheme standard fee — 2 or more stocks 1,652 Mutual recognition incoming application standard fee — single stock 498 Mutual recognition incoming application standard fee — 2 or more stocks 747 Outgoing mutual recognition / decentralised supplement 621 National variation — registration and national rules scheme 373 National variation — reduced rate — registrations and national rules scheme 187 Mutual recognition incoming variation 249 Mutual recognition incoming variation — reduced rate 124 Variation — outgoing mutual recognition / decentralised supplement 187 Bulk variation for multiple changes to the masterfile 2,245 Fees for applications in relation to traditional herbal medicinal products National applications for certificates of traditional-use registration National application 5,385 National application where there is a monograph 3,305 Each additional form (same time) 4,486 Each additional strength (same time) 579 Additional drug master file submitted 3,581 Extension applications First additional form 5,385 Each additional form (same time) 4,485 First additional strength 2,429 Each additional strength (same time) 579 Applications for certificates of traditional-use registration under mutual recognition procedure and decentralised procedure Mutual recognition incoming 3,765 Mutual recognition incoming — each additional form (same time) 2,520 Mutual recognition incoming — each additional strength (same time) 579 Outgoing mutual recognition / decentralised supplement 4,897 Decentralised outgoing/incoming 5,385 Each additional form (same time) 4,486 Each additional strength (same time) 579 Traditional herbal medicinal products — national variations Type IB variation — national 413 Type IB variation — reduced rate 210 Type II standard variation 441 Type II standard variation — reduced rate 220 Type II complex variation 2,313 Bulk variation for multiple changes 4,627 Traditional herbal medicinal products — mutual recognition variations Type IB variation — mutual recognition incoming 297 Type IB variation — mutual recognition incoming — reduced rate 154 Type IB variation — outgoing mutual recognition supplement 303 Type II standard — mutual recognition incoming 297 Type II standard — mutual recognition incoming — reduced rate 154 Type II standard — outgoing mutual recognition supplement 297 Type II complex — mutual recognition incoming 1,581 Type II complex — outgoing mutual recognition supplement 462 Fees for export certificates and certification of documents Standard 162 Fast track 305 Annual maintenance fees Marketing authorisations and registrations First 10 marketing authorisations 716 Additional marketing authorisations 894 Dormant marketing authorisations 463 Parallel import licence 124 Parallel import licence — Dual pack 61 Certificate of registration — homeopathic medicinal products 61 Certificate of traditional-use registration — traditional herbal medicinal products 124 Manufacturer’s authorisations Major site (more than 250 employees) 18,363 Large site (150-250 employees) 12,241 Medium site (50-149 employees) 8,162 Small site (less than 50 employees) 4,079 Homeopathic manufacturing site 1,102 Wholesaler’s authorisations Large full line 3,053 Medium full line/ short line 1,736 Small short line 661 Minor site / Procure & supply 441 Active substances register Active substances distributor 275 Active substances importer 551 Active substances manufacturer 1,102 Organ establishment authorisations Major establishment (more than 250 employees) 18,363 Large establishment (150-250 employees) 12,241 Medium establishment (50-149 employees) 8,162 Small establishment (less than 50 employees) 4,079 Minor establishment (less than 5 employees) 1,102 Project fees Project application without ethical approval 2,000 Fast track project application 2,000 Breeder/Supplier/User Authorisation fees Band 1: Small establishment with no animal facilities or establishment with 1-3 individual authorisation holders 275 Band 2: Establishment with 4-10 individual authorisation holders 550 Band 3: Establishment with 11-20 individual authorisation holders 850 Band 4: Establishment with 21-50 individual authorisation holders 1,600 Band 5: Establishment with 51-100 individual authorisation holders 3,250 Band 6: Establishment with 101-150 individual authorisation holders 5,500 Band 7: Establishment with 151 — 200 individual authorisation holders 8,000 Band 8: Establishment with >201 individual authorisation holders 10,500 Individual authorisation fees Application fee 260 Annual fee 260 Once-off authorisation — procedural training for a period of two months or less (reduced fee) 100 Fees for follow-up inspections Per day (per member of the inspection team) 1,640 Part of day (per hour, per member of the inspection team) 235 Inspection/Audit fees (other than inspections in relation to the protection of animals used for scientific purposes) Per day (per member of the inspection team) 1,640 Part of day (per hour, per member of the inspection team) 235 Enforcement fees Manufacturers Major site (more than 250 employees) 2,644 Large site (150-250 employees) 1,983 Medium site (50-149 employees) 661 Small site (less than 50 employees) 220 Wholesalers Large full line 661 Medium full line / short line 220 Marketing authorisation / parallel import licence holders > 50 marketing authorisations / parallel import licences 3,470 31-50 marketing authorisations / parallel import licences 1,102 16-30 marketing authorisations / parallel import licences 661 6-15 marketing authorisations / parallel import licences 220 (Note: Companies classed as both manufacturer and wholesaler are charged the higher of the two applicable charges. Marketing authorisation holders pay the marketing authorisation holder fee in addition to any manufacturer’s authorisation / wholesaler’s authorisation fee.) Fees in relation to medical devices Manufacturers and authorised representatives — annual fees Manufacturer — more than 150 employees 30,000 Manufacturer — 100-150 employees 20,000 Manufacturer — 50-99 employees 15,000 Manufacturer — 16-49 employees 5,000 Manufacturer — 5-15 employees 1,250 Manufacturer — less than 5 employees or annual turnover of less than €500,000 250 Authorised representative/legal manufacturer which is not a manufacturer (of medical devices) (maximum of €5,000) 1,250 (Note: Where one organisation has multiple manufacturing sites based in the State, the organisation will be charged per manufacturing site to a maximum fee of €60,000.) Distributors — annual fees Large distributor (turnover greater than €15 million) 4,500 Medium distributor (turnover €3-€15 million) 2,500 Small distributor (turnover under €3 million) 1,250 Distributor turnover less than €500,000 250 Notified Body — annual fees 5,000 Summary evaluation review fees Medical Devices using starting materials for which a TSE certificate of suitability has been submitted 1,000 Medical Devices using starting materials for which a TSE certificate of suitability has not been submitted 3,000 Certificates of free sale for medical devices Certificate of free sale (4 certificates per request) 250 Duplicate certificates of free sale — each (available at time of request) 23 Given under my official seal, 11 December 2018. SIMON HARRIS, Minister for Health. EXPLANATORY NOTE (This note is not part of the instrument and does not purport to be a legal instrument.) The purpose of these Regulations is to provide for the revision of fees payable to the Health Products Regulatory Authority (formerly the Irish Medicines Board) pursuant to Section 13 of the Irish Medicines Board Act 1995 . These Regulations revoke the Health Products Regulatory Authority (Fees) Regulations 2018 ( S.I. No. 208 of 2018 ). These Regulations may be cited as the Health Products Regulatory Authority (Fees) (No. 2) Regulations 2018. 1 OJ No. L 311, 28.11.2001, p. 67. 2 OJ No. L 334, 12.12.2008, p. 7. Privacy Statement Accessibility European Legislation Identifier (PDF) Open Data License Ráiteas Príobháideachais Inrochtaineacht Aitheantóir Eorpach Reachtaíochta (ELI) Ceadúnas Sonraí Oscailte Liosta Fianán © Government of Ireland. Oireachtas Copyright Material is reproduced with the permission of the Houses of the Oireachtas © Rialtas na hÉireann. Atáirgtear ábhar faoi Chóipcheart le cead ó Thithe an Oireachtais